European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society
Open Access
- 1 November 2012
- journal article
- practice guideline
- Published by Wiley in European Journal of Neurology
- Vol. 19 (11) , 1385-1396
Abstract
Background: Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis‐Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society.Objectives: To provide an evidence‐based update of new treatments published since 2005 for the management of RLS.Methods: First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating.Recommendations: Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short‐term treatment for RLS. However, for the long‐termtreatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.Keywords
This publication has 92 references indexed in Scilit:
- Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patientsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2012
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Gabapentin Enacarbil in Subjects with Restless Legs SyndromeJournal of Clinical Sleep Medicine, 2011
- Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of moodSleep Medicine, 2011
- Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled studyJournal of Neurology, 2010
- Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled StudyMayo Clinic Proceedings, 2010
- A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndromeSleep Medicine, 2009
- Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2008
- Intradialytic Aerobic Exercise Training Ameliorates Symptoms of Restless Legs Syndrome and Improves Functional Capacity in Patients on HemodialysisASAIO Journal, 2008
- State of the art in restless legs syndrome therapy: Practice recommendations for treating restless legs syndromeMovement Disorders, 2007
- Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trialMovement Disorders, 2006